2025-06-03-Jefferies-阿尔托神经科学（ANRO）_新资产收购为精准精神病学目标增添新动力_9页_1mb

Summary of USA Biotechnology Equity Research on Alto Neuroscience (ANRO)

Alto Neuroscience (ANRO) recently received a "Buy" rating with a price target of $15.00 from Jefferies, representing a 477% upside from the current price of $2.60. This follows a small acquisition of two dopamine combination products, adding catalysts to the company's precision psychiatry platform. The key product is ALTO-207, a fixed-dose combination of pramipexole and ondansetron, designed to treat treatment-resistant depression (TRD) and Parkinson's disease, with a Phase IIb trial expected to start in mid-2026 and provide data by 2027. The trial leverages ANRO's proprietary EEG biomarkers to select responsive patients, aiming to rebuild investor confidence in its precision medicine approach. Supporting data from prior Phase II studies show efficacy in depression, with high unmet need in TRD. ALTO-208, an antiemetic combination, is also being developed for Parkinson's. Financially, ANRO has secured funding and expects no need to de-prioritize assets. Risks include clinical trial outcomes, regulatory hurdles, and commercialization challenges.

ANRO's other programs, like ALTO-300 for major depression, are advancing with Phase IIb data expected later in 2026. Milestones include expanding Phase II development plans, which could drive further growth. However, the company faces significant risks in achieving its valuation targets due to the high likelihood of clinical and regulatory complications. Overall, the acquisition strengthens ANRO's pipeline, but investors should monitor trial progress and market dynamics closely.